Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.
Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...
Patients with RA had a nearly 1.8-fold higher risk for incident heart failure compared with those without RA after adjusting for cardiovascular disease risk factors. (HealthDay News) — Rheumatoid ...